The partnership will conduct patient surveillance for early pancreatic cancer using Biological Dynamics’ ExoVita Pancreas Assay. Credit: Nemes Laszlo / Shutterstock.com.

Biological Dynamics has signed a multi-year agreement with the Pancreatic Cancer Early Detection (PRECEDE) Consortium to improve the surveillance of early pancreatic cancer.

Leveraging Biological Dynamics’s ExoVita Pancreas Assay, powered by the Verita platform, the partnership will focus on conducting patient surveillance for this condition.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The Verita platform is intended to target and isolate blood-based exosomal protein biomarkers, thereby supporting high-sensitivity detection of early-stage cancer.

The partnership expedites the enrolment of a minimum of 5,000 patients into Biological Dynamics’s ExoLuminate study.

The clinical study spans multiple locations and aims to identify early pancreatic ductal adenocarcinoma in individuals at a higher risk of pancreatic cancer.

See Also:

It is focused on validating the ExoVita Pancreas assay for various high-risk patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Biological Dynamics medical director and ExoLuminate study principal investigator Harmeet Dhani said: “In order to go from a 12.5% survival rate to a 50% survival rate within five years, the answer will lie in significantly improving surveillance and accelerating detection of pancreatic cancer at stages I or II with a blood-based assay like ExoVita Pancreas.”

Biological Dynamics is said to be the first liquid biopsy partner of PRECEDE, which is an international, multi-institutional group of experts focused on improving survival rates for patients with pancreatic cancer.

Biological Dynamics CEO and director Paul Billings said: “We’re thrilled to work with PRECEDE to advance our shared goal of increasing pancreatic cancer survival rates and to further clinically validate the Verita platform and ExoVita assay for detecting cancer earlier using a new generation of exosome-based biomarkers and technology.”